180 Life Sciences Corp (ATNF)
1.49
0.00 (0.00%)
USD |
NASDAQ |
Jun 25, 16:00
1.49
0.00 (0.00%)
After-Hours: 20:00
180 Life Sciences Research and Development Expense (Annual): 2.784M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 2.784M |
| December 31, 2022 | 2.433M |
| December 31, 2021 | 3.948M |
| Date | Value |
|---|---|
| December 31, 2020 | 2.293M |
| December 31, 2019 | 2.035M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
2.035M
Minimum
2019
3.948M
Maximum
2021
2.699M
Average
2.433M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Seelos Therapeutics Inc | 30.12M |
| GT Biopharma Inc | 6.466M |
| Altimmune Inc | 65.80M |
| Oragenics Inc | 15.49M |
| MAIA Biotechnology Inc | 11.11M |